BioSpace News Archive

The company is now part of the FDA Digital Health Software Pre-certification Pilot Program

A replay of the audiocast will be available following the live presentation.

Evolent Health, a company providing an integrated value-based care platform to the nation’s leading providers and payers, today announced that its partner Passport Health Plan received notification from the Kentucky Cabinet for Health and Family Services (CHFS) that Passport has not been awarded a Kentucky managed Medicaid contract for the next contract period.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its Chief Financial Officer, Marc Belsky, will present a corporate overview at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 1:50pm EST.

Varian (NYSE: VAR) today announced Dr. Michelle Le Beau, professor of Medicine, University of Chicago and director, University of Chicago Medicine Comprehensive Cancer Center, has been appointed to the Varian Board of Directors, effective November 27, 2019.

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company’s Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company’s new Chief Medical Officer, an option to purchase 300,000 shares of the Company’s common stock with an exercise price of $1.01 per share,

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its Chief Operating Officer, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; and one additional employee, on November 13, 2019.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the U.S. launch of an automated workflow for QuantiFERON-TB Plus (QFT-Plus), the fourth-generation modern gold standard for latent tuberculosis (TB) detection, on DiaSorin’s LIAISON platforms.

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced today that the first patient has been enrolled in EXCELLENCE, the Phase III pivotal clinical trial for TLC599 in patients with osteoarthritis (OA) knee pain.

The presentation will be available on Medivir’s website after completion of the conference.